Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives. Li Z, Lu S. J Thorac Oncol 2023;18:1625-1628.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li Z, Lu S. Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives. J Thorac Oncol 2023;18:1625-1628.
PMID: 37993215